BerGenBio ASA

🌟 CEO Olav Hellebø presented company updates at the DNB Healthcare Conference this week! 👇 Key takeaways from the presentation: 1️⃣ We are focused on developing bemcentinib in 1L STK11m NSCLC 2️⃣ BerGenBio was a “first-mover” in the 1L STK11m space and bemcentinib is the leading AXL inhibitor in development for lung cancer 3️⃣ The safety and tolerability of adding bemcentinib to the standard of care in 1L NSCLC has been established 4️⃣ Our ongoing Phase 2a BGBC016 study is proceeding with an interim analysis expected in the first part of 2025 🔗 Link to the presentation here: https://lnkd.in/dVDE7mgU #DNB #Bemcentinib #NSCLC #STK11 #AXL

ℹ️ Lung cancer is the leading cause of cancer death worldwide. ❤️ November marks Lung Cancer Awareness Month, and we stand with those impacted by lung cancer. 💊 Our compound, bemcentinib, targets Non-Small Cell Lung Cancer patients with mutation in the STK11 gene. #LungCancerAwarenessMonth #bemcentinib #NSCLC

🌟 Olav Hellebø is the new CEO of BerGenBio ASA as of today! 💊 He brings three decades of experience in the pharmaceutical and biotechnology industries. "BerGenBio is at the forefront of exploring highly selective AXL inhibition as a therapeutic enhancement for the large number of patients with non-squamous non -small cell lung cancer with mutations in the STK11 gene. I am thrilled to join the company and look forward to collaborating with the board and team to advance the candidate drug, bemcentinib, through the next stages of clinical development and to take BerGenBio to the next phase", said Olav Hellebø.

Today, BerGenBio ASA announced financial results for Q3 2024 and provided a business update! Highlights, including post period: 🩸 Ph1b enrollment is completed, and acceptable safety and pharmacokinetics were announced. 🌎 Ph2a continues to accrue patients in the US and in Europe. 📈 New published data from MD Anderson continues to support the need for improved therapies in target patient population. 💉 The board decided to focus fully on bemcentinib and discontinue all tilvestamab activities after extensive partnership discussions have failed to identify an attractive licensing opportunity.   The recording of the webcast, report, and presentation can be found here: https://lnkd.in/daHq6x6Y #bemcentinib #biotech #cancerresearch

🧬 Learn more about BerGenBio’s activities in treating NSCLC patients with STK11 mutations 🌟 Dr. Rajwanth Veluswamy, MD, Assistant Professor in Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai and Principal investigator in BerGenBio ASA’s BGBC016 clinical trial, talks about the poor prognosis for STK11m NSCLC patients and new treatments designed to “super charge” patients’ immune responses to cancer, of which BerGenBio ASA’s AXL targeted compound bemcentinib is a leading example. ℹ️ More information about the trial can be found here: https://lnkd.in/dP3mdC9v #NSCLC #STK11 #AXL #bemcentinib

📈 Ph1b data support safety, predictable PK, and adequate plasma exposure! 💊 "The data show that #bemcentinib has a manageable safety profile and gives us increased confidence in continuing the BGBC016 clinical trial. The global trial is currently enrolling patients in Phase 2a targeting patients with a mutation in the #STK11 gene, and we look forward to sharing the first preliminary data as they mature", says BerGenBio ASA CEO, Martin Olin. #cancerresearch #bemcentinib #STK11 #NSCLC

Today, BerGenBio ASA reported solid clinical and financial progress for the second quarter of 2024. The recording of the webcast, report, and presentation can be found here: https://lnkd.in/gTXUPGRn #bemcentinib #biotech #cancerresearch

BerGenBio ASA and Tempus AI join forces to establish a prospective synthetic control arm! This will provide a contextual benchmark for the BGBC016 Ph2a study results and potentially accelerate the development of BerGenBio ASA’s selective #AXL inhibitor #bemcentinib in 1L #NSCLC patients with mutations in the #STK11 gene. #bemcentinib #AXL #NSCLC #STK11 

On #WorldLungCancerDay, we stand with those impacted by lung cancer. As one of the most common cancers in the world, we need more treatments. Our compound #bemcentinib targets Non-Small Cell Lung Cancer patients with mutation in the #STK11 gene. #WorldLungCancerDay #cancerresearch #bemcentinib

BioTuesdays writes about BerGenBio ASA and our pioneering work to develop #AXL targeted therapies👇 #AXL #bemcentinib #NSCLC